278 related articles for article (PubMed ID: 23188630)
1. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.
Song B; Liu XS; Rice SJ; Kuang S; Elzey BD; Konieczny SF; Ratliff TL; Hazbun T; Chiorean EG; Liu X
Mol Cancer Ther; 2013 Jan; 12(1):58-68. PubMed ID: 23188630
[TBL] [Abstract][Full Text] [Related]
2. Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Li J; Wang R; Schweickert PG; Karki A; Yang Y; Kong Y; Ahmad N; Konieczny SF; Liu X
Cell Cycle; 2016; 15(5):711-9. PubMed ID: 26890815
[TBL] [Abstract][Full Text] [Related]
3. Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress.
Song B; Liu XS; Davis K; Liu X
Mol Cell Biol; 2011 Dec; 31(23):4844-56. PubMed ID: 21947279
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
5. A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer.
Jimeno A; Rubio-Viqueira B; Rajeshkumar NV; Chan A; Solomon A; Hidalgo M
Mol Cancer Ther; 2010 Feb; 9(2):311-8. PubMed ID: 20103597
[TBL] [Abstract][Full Text] [Related]
6. Role for Plk1 phosphorylation of Hbo1 in regulation of replication licensing.
Wu ZQ; Liu X
Proc Natl Acad Sci U S A; 2008 Feb; 105(6):1919-24. PubMed ID: 18250300
[TBL] [Abstract][Full Text] [Related]
7. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1.
Zhao XY; Nie CL; Liang SF; Yuan Z; Deng HX; Wei YQ
Biomed Pharmacother; 2012 Dec; 66(8):597-602. PubMed ID: 23153503
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
9. RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
Yu C; Zhang X; Sun G; Guo X; Li H; You Y; Jacobs JL; Gardner K; Yuan D; Xu Z; Du Q; Dai C; Qian Z; Jiang K; Zhu Y; Li QQ; Miao Y
J Cell Mol Med; 2008 Dec; 12(6A):2334-49. PubMed ID: 18266952
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer.
Tang S; Hang Y; Ding L; Tang W; Yu A; Zhang C; Sil D; Xie Y; Oupický D
Mol Pharm; 2021 Dec; 18(12):4448-4458. PubMed ID: 34699242
[TBL] [Abstract][Full Text] [Related]
11. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
[TBL] [Abstract][Full Text] [Related]
12. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis.
Singh R; Peng S; Viswanath P; Sambandam V; Shen L; Rao X; Fang B; Wang J; Johnson FM
EMBO Mol Med; 2019 May; 11(5):. PubMed ID: 31040125
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
15. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
Su YH; Hsu TW; Chen HA; Su CM; Huang MT; Chuang TH; Leo Su J; Hsieh CL; Chiu CF
J Cell Physiol; 2021 Jun; 236(6):4420-4434. PubMed ID: 33184874
[TBL] [Abstract][Full Text] [Related]
16. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
17. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
19. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Kolberg M; Bruun J; Murumägi A; Mpindi JP; Bergsland CH; Høland M; Eilertsen IA; Danielsen SA; Kallioniemi O; Lothe RA
Mol Oncol; 2017 Sep; 11(9):1156-1171. PubMed ID: 28556483
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
